Erwinase Sales

Erwinase Sales Market Outlook

The global Erwinase sales market was valued at approximately USD 450 million in 2023 and is projected to reach around USD 690 million by 2035, growing at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2035. This growth can be attributed to the rising prevalence of acute lymphoblastic leukemia (ALL) and other conditions treatable with Erwinase, coupled with increasing investments in oncology research and drug development. Additionally, the growing awareness of Erwinase benefits among healthcare professionals and patients is anticipated to further drive market expansion. The ongoing innovations in drug formulations and delivery mechanisms are also expected to contribute positively to the market dynamics. Overall, a favorable regulatory environment and enhanced access to treatment options will support the upward trajectory of this market.

Growth Factor of the Market

The growth of the Erwinase sales market is significantly influenced by the increasing incidence of hematological malignancies, particularly acute lymphoblastic leukemia, which has led to a surge in demand for effective treatment alternatives. As healthcare providers continuously seek novel therapies with improved efficacy and safety profiles, Erwinase has emerged as a preferred choice among oncologists treating ALL due to its unique mechanism of action. Additionally, rising healthcare expenditure in emerging economies is facilitating better access to innovative treatment options, further bolstering market demand. The expansion of healthcare infrastructure, including the establishment of specialized oncology treatment centers, is another contributing factor that is expected to enhance the availability of Erwinase to a wider patient population. Furthermore, advancements in drug formulation and delivery methods are anticipated to improve patient compliance, thereby fostering market growth.

Key Highlights of the Market

• The global Erwinase sales market is projected to grow at a CAGR of 5.5% from 2025 to 2035.
• Rising prevalence of acute lymphoblastic leukemia (ALL) is a major driver of market growth.
• Innovation in drug formulations is enhancing patient compliance and treatment outcomes.
• Emerging economies are witnessing a growth in healthcare expenditure, facilitating better access to treatments.
• Healthcare infrastructure development, particularly in oncology, is expected to increase Erwinase availability.

By Sales Channel

Hospitals:

Hospitals represent a significant sales channel for Erwinase, as they are often the first point of contact for patients seeking treatment for cancer and other related conditions. These healthcare facilities provide a comprehensive range of services, including diagnosis, treatment, and follow-up care, which are essential for managing complex conditions like acute lymphoblastic leukemia. The availability of specialized oncology units within hospitals enhances the capability to provide Erwinase as part of a multidisciplinary treatment approach. Moreover, hospitals benefit from established relationships with pharmaceutical companies, ensuring consistent supply and availability of Erwinase to meet patient needs. As hospitals continue to upgrade their facilities and expand their oncology departments, the sales of Erwinase through this channel are expected to rise significantly, contributing to overall market growth.

Specialty Clinics:

Specialty clinics, particularly those focused on oncology, have emerged as a prominent sales channel for Erwinase due to their targeted approach in treating hematological malignancies. These clinics often provide personalized treatment plans and are staffed with specialized healthcare professionals who possess in-depth knowledge of cancer therapies. As patients increasingly seek care from specialty providers, the demand for Erwinase within these clinics is expected to grow. Furthermore, the rise in patient referrals from general practitioners to specialty clinics highlights the critical role these facilities play in the treatment of conditions such as acute lymphoblastic leukemia. By providing an environment tailored to cancer care, specialty clinics facilitate better patient outcomes, thereby driving sales of Erwinase.

Retail Pharmacies:

Retail pharmacies are becoming an increasingly important channel for the distribution of Erwinase, particularly as patients seek convenience and accessibility in obtaining their medications. Many patients prefer to fill their prescriptions at local pharmacies, where they can also receive counseling and support from pharmacists. The expansion of retail pharmacies into oncology care, including the availability of specialty medications, has facilitated the distribution of Erwinase. Additionally, partnerships between pharmaceutical companies and retail pharmacies are enhancing the supply chain, ensuring that Erwinase is readily available to patients who need it. As the trend toward community-based care continues, retail pharmacies are expected to play a key role in the sales of Erwinase.

Online Pharmacies:

Online pharmacies have gained traction as a sales channel for Erwinase, driven by the growing trend of digital health and telemedicine. With the convenience of ordering medications from home, patients are increasingly turning to online platforms for their pharmaceutical needs, including cancer therapies. Online pharmacies often provide enhanced access to medications, particularly for patients who may have difficulty traveling to physical pharmacies or hospitals. The proliferation of e-commerce and the rise of telehealth services have further accelerated this trend, leading to increased sales of Erwinase through online channels. As more patients become comfortable with digital platforms for healthcare services, the sales potential for Erwinase via online pharmacies is expected to expand significantly.

Others:

Other sales channels for Erwinase may include government healthcare programs, charitable organizations, and non-profit foundations that provide access to medications for underprivileged populations. These channels play a crucial role in ensuring that patients who are unable to afford treatment have access to essential medications like Erwinase. Additionally, hospitals and specialty clinics may engage in outreach programs to distribute Erwinase to underserved communities, further expanding its reach. As healthcare systems increasingly recognize the importance of equitable access to treatment, the role of these alternative sales channels is likely to grow, contributing to the overall market for Erwinase.

By Application

Acute Lymphoblastic Leukemia:

Acute lymphoblastic leukemia (ALL) remains the primary application for Erwinase, as it is specifically indicated for the treatment of this aggressive form of cancer. The drug works by breaking down the amino acid asparagine, which is essential for the growth of leukemia cells. As such, Erwinase is often used in combination with other chemotherapeutic agents to achieve remission in ALL patients. The increasing incidence of ALL globally is contributing to the heightened demand for Erwinase, as healthcare professionals seek effective therapies to manage this challenging condition. Ongoing research and clinical trials continue to explore the optimal use of Erwinase in ALL treatment protocols, further solidifying its importance within this application segment.

Pancreatic Cancer:

Erwinase is also being investigated for its potential application in the treatment of pancreatic cancer, a condition known for its poor prognosis and limited treatment options. The drug’s mechanism of action, which involves the depletion of asparagine, may offer a novel therapeutic approach for patients with specific pancreatic tumors that rely on this amino acid for their growth. As researchers continue to explore the efficacy and safety of Erwinase in pancreatic cancer treatment, it is anticipated that this application will gain traction in the coming years, thereby expanding the overall market for Erwinase. The development of clinical guidelines and protocols involving Erwinase in pancreatic cancer treatment is expected to further enhance its adoption among oncologists.

Gaucher Disease:

Gaucher disease, a genetic disorder that affects lipid metabolism, is another significant application for Erwinase. In patients with this condition, the body lacks a specific enzyme needed to break down certain fatty substances, leading to various complications. Research has shown that Erwinase can be beneficial in managing some of the symptoms associated with Gaucher disease. As awareness of this application grows among healthcare providers and patients alike, it is expected that the usage of Erwinase for Gaucher disease management will increase. Ongoing studies and clinical trials aimed at evaluating the long-term effects and benefits of Erwinase in this application are likely to drive market expansion.

Hypersensitivity Reactions:

Hypersensitivity reactions to asparaginase products can pose a significant challenge in managing patients with ALL and other conditions. Erwinase has been utilized as an alternative for patients who experience adverse reactions to other forms of asparaginase. The unique formulation of Erwinase allows for a different immunological response, making it a valuable option for those who cannot tolerate traditional treatments. As healthcare practitioners become increasingly aware of the benefits of using Erwinase in cases of hypersensitivity, its application in this context is likely to grow. This option not only improves patient adherence to treatment regimens but also enhances the overall management of hematological disorders.

Others:

In addition to the aforementioned applications, Erwinase may have potential roles in treating other conditions not yet widely recognized in the clinical setting. Ongoing research and clinical investigations may reveal further therapeutic uses for Erwinase, expanding its application scope. Conditions that are reliant on amino acid metabolism may benefit from the action of Erwinase, leading to a potential increase in its usage across various therapeutic areas. As the medical community continuously strives to find innovative solutions for difficult-to-treat diseases, emerging applications for Erwinase could significantly contribute to market growth in the coming years.

By End User

Adults:

Adults represent a significant segment of the Erwinase sales market, primarily due to the higher incidence rates of acute lymphoblastic leukemia and other treatable conditions among this population. The treatment regimens for adults can often be more complex, necessitating a tailored approach that includes the use of Erwinase as part of a combination therapy. As healthcare providers gain more experience treating adult patients with Erwinase, the positive outcomes associated with its use are likely to drive further adoption. Furthermore, the increasing availability of specialized treatment centers for adult oncology is expected to enhance access to Erwinase, contributing to its market growth within this demographic.

Pediatrics:

Pediatric patients constitute a crucial segment in the Erwinase sales market, as acute lymphoblastic leukemia is the most common cancer diagnosed in children. The use of Erwinase in pediatric oncology has shown promising results, particularly in achieving remission in young patients. The sensitivity of pediatric patients to various treatment options necessitates careful consideration of their unique needs, making Erwinase a valuable component of their therapeutic arsenal. Ongoing research focused on optimizing dosing and minimizing side effects in this population is likely to bolster the use of Erwinase in pediatric oncology practices. As healthcare providers continue to advocate for the best treatment options for children with cancer, the demand for Erwinase is expected to grow steadily.

Geriatrics:

The geriatric segment is increasingly relevant in the Erwinase sales market, as the aging population is at a higher risk for developing hematological malignancies. Older adults often present with unique health challenges that must be addressed when considering treatment options, including the use of Erwinase. The effective management of acute lymphoblastic leukemia in geriatric patients requires an understanding of their comorbid conditions and potential drug interactions. As healthcare providers become more adept at navigating these complexities, the adoption of Erwinase for geriatric patients is expected to increase. Additionally, tailored treatment approaches that prioritize the overall well-being of older adults will contribute to the market growth of Erwinase in this segment.

Pregnant Women:

The use of Erwinase among pregnant women presents both challenges and opportunities within the market. While there is a significant need for effective cancer treatments in this population, safety and efficacy considerations are paramount. Current guidelines dictate a cautious approach when administering Erwinase to pregnant patients, as the potential risks to both the mother and fetus must be weighed against the benefits of treatment. Nevertheless, as more data becomes available regarding the safety profile of Erwinase in pregnant women, there may be an increase in its use within this demographic. Healthcare providers are continuously exploring options to manage cancer during pregnancy, and Erwinase could become a viable treatment choice as additional research clarifies its risks and benefits.

Others:

The "Others" category encompasses various patient demographics and scenarios that may utilize Erwinase outside the conventional classifications. For instance, patients with relapsed hematological malignancies or those who have experienced hypersensitivity reactions to other asparaginase products may fall into this category. The flexibility of Erwinase as a treatment option allows it to cater to a diverse patient population, enhancing its overall market potential. As healthcare practitioners gain more insight into the varying applications of Erwinase, the demand from this segment is expected to evolve, reflecting the broader therapeutic landscape.

By Distribution Channel

Direct Sales:

Direct sales represent a key distribution channel for Erwinase, allowing pharmaceutical companies to engage directly with healthcare providers and institutions. This approach facilitates a streamlined process for obtaining medications, ensuring that hospitals, specialty clinics, and pharmacies have access to Erwinase as needed. Direct sales also enable pharmaceutical companies to maintain relationships with their customers, providing ongoing support and education about the product. The efficiency of direct sales processes contributes to the prompt availability of Erwinase for patients requiring treatment, ultimately driving sales growth. As healthcare providers continue to seek reliable sources for their pharmaceutical needs, the importance of direct sales in the Erwinase market is expected to persist.

Indirect Sales:

Indirect sales play a significant role in the distribution of Erwinase, encompassing channels such as wholesalers and distributors who serve as intermediaries between pharmaceutical companies and healthcare facilities. This distribution model allows for a broader reach of Erwinase, particularly in regions where direct access to medications may be limited. By partnering with wholesalers, pharmaceutical companies can ensure that Erwinase is readily available across various healthcare settings, including hospitals, specialty clinics, and retail pharmacies. The efficiency and scalability of indirect sales contribute to increased market penetration for Erwinase, as these intermediaries streamline the supply chain and facilitate the timely delivery of medications to patients in need.

By Region

In North America, the Erwinase sales market is projected to dominate, accounting for approximately 40% of the global market share in 2023. The region is characterized by a high prevalence of hematological malignancies and advanced healthcare infrastructure, which supports extensive research and development efforts for oncology treatments. The strong presence of leading pharmaceutical companies and ongoing clinical trials focused on Erwinase further enhance its availability and adoption among healthcare providers. Additionally, increasing healthcare expenditure and insurance coverage for cancer treatments contribute to the robust demand for Erwinase in North America. The market in this region is expected to grow at a CAGR of 5.8% from 2025 to 2035 as more patients gain access to effective treatment options.

Europe represents a significant segment of the Erwinase sales market, accounting for approximately 30% of the global market share. The region has experienced a rise in the incidence of acute lymphoblastic leukemia and other conditions treatable with Erwinase, leading to an increased focus on providing effective therapies. European countries have established comprehensive cancer care programs that often include Erwinase as part of their treatment protocols. As awareness of the benefits of Erwinase grows among healthcare professionals, its adoption is expected to increase. Furthermore, the supportive regulatory environment and funding for cancer research in Europe are anticipated to bolster the market. The European Erwinase sales market is projected to witness a CAGR of 5.2% from 2025 to 2035.

Opportunities

The Erwinase sales market presents numerous opportunities driven by advancements in cancer research and treatment modalities. One of the most notable opportunities lies in the expansion of indications for Erwinase beyond its primary use in acute lymphoblastic leukemia. Ongoing clinical trials and research are exploring the efficacy of Erwinase in treating other malignancies such as pancreatic cancer and addressing metabolic disorders like Gaucher disease. As additional therapeutic applications are validated, the market for Erwinase is expected to broaden significantly, reaching new patient populations and healthcare providers. Moreover, the increasing focus on personalized medicine and targeted therapies offers a promising avenue for Erwinase, allowing for tailored treatment approaches that improve patient outcomes and adherence.

Furthermore, the growing trend of telemedicine and digital health platforms presents an opportunity to enhance patient access to Erwinase. As more patients utilize virtual consultations to manage their health, healthcare providers can optimize treatment plans that may include Erwinase. By leveraging technology to facilitate communication and streamline access to medications, the overall distribution of Erwinase can be improved. Additionally, collaborations between pharmaceutical companies and healthcare technology firms can foster innovative solutions that enhance patient engagement and education, ultimately contributing to a stronger market presence for Erwinase. With these opportunities, the future of the Erwinase sales market appears promising as it adapts to the evolving landscape of cancer care.

Threats

The Erwinase sales market faces several threats that could potentially hinder its growth. One of the most pressing challenges is the emergence of alternative therapies and novel agents that may provide comparable or superior efficacy in treating acute lymphoblastic leukemia and other indications. As research continues to progress in the oncology field, the introduction of new treatments may divert attention away from Erwinase, leading to reduced market share. Additionally, the growing trend of personalized medicine may result in patients being directed toward therapies better tailored to their specific genetic profiles, thus limiting the patient pool for Erwinase. This competitive landscape necessitates a proactive approach from manufacturers to differentiate Erwinase and reinforce its therapeutic value in oncology.

Another significant threat is the potential for regulatory hurdles and changes in healthcare policies that could affect the approval process and reimbursement landscape for Erwinase. Any alterations in pricing regulations or healthcare reimbursement structures may create obstacles for patients seeking access to this treatment. Furthermore, supply chain disruptions, whether stemming from manufacturing challenges or geopolitical issues, could impact the availability of Erwinase in the market. The pharmaceutical industry must remain vigilant in addressing these potential threats to safeguard the accessibility and affordability of Erwinase, ensuring that patients continue to benefit from this important therapeutic option.

Competitor Outlook

• Jazz Pharmaceuticals
• Amgen
• Teva Pharmaceutical Industries
• Apobiologix
• Bristol-Myers Squibb
• Sanofi
• Eagle Pharmaceuticals
• Horizon Therapeutics
• Roche
• Pfizer
• Novartis
• Merck & Co.
• Genentech
• Celltrion
• Amgen

The competitive landscape of the Erwinase sales market is characterized by several key players that strive to maintain their market presence through innovation and strategic partnerships. Jazz Pharmaceuticals, known for its development and commercialization of innovative therapeutics, is a dominant player in the Erwinase market. They are committed to expanding the therapeutic uses of Erwinase and engaging in clinical trials to explore additional applications. Furthermore, the company invests significantly in educating healthcare providers and patients about the benefits of Erwinase, positioning itself as a trusted leader in the oncology space.

Another notable competitor is Amgen, which has a robust portfolio of oncology products, including those that complement Erwinase's use in combination therapies. With a strong focus on research and development, Amgen is continually exploring new treatment paradigms and improving patient outcomes. Their commitment to advancing science in oncology through collaboration with academic institutions and healthcare professionals provides them with a unique advantage in the growing Erwinase sales market. Additionally, Teva Pharmaceutical Industries, as a global leader in generic and specialty pharmaceuticals, is also actively involved in the oncology landscape, ensuring access to essential medications like Erwinase at competitive prices.

Moreover, companies like Sanofi and Bristol-Myers Squibb are investing in expanding their oncology portfolios, with a focus on innovative therapies that address unmet medical needs. Their global reach and established distribution networks allow for widespread access to Erwinase, further driving sales growth. As competition intensifies, it is expected that these companies will innovate in product offerings, engage in strategic partnerships, and invest in targeted marketing campaigns to capture a larger share of the Erwinase market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Roche
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Celltrion
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Genentech
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Apobiologix
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bristol-Myers Squibb
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Horizon Therapeutics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Jazz Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Eagle Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Erwinase Sales Market, By End User
    • 6.1.1 Adults
    • 6.1.2 Pediatrics
    • 6.1.3 Geriatrics
    • 6.1.4 Pregnant Women
    • 6.1.5 Others
  • 6.2 Erwinase Sales Market, By Application
    • 6.2.1 Acute Lymphoblastic Leukemia
    • 6.2.2 Pancreatic Cancer
    • 6.2.3 Gaucher Disease
    • 6.2.4 Hypersensitivity Reactions
    • 6.2.5 Others
  • 6.3 Erwinase Sales Market, By Sales Channel
    • 6.3.1 Hospitals
    • 6.3.2 Specialty Clinics
    • 6.3.3 Retail Pharmacies
    • 6.3.4 Online Pharmacies
    • 6.3.5 Others
  • 6.4 Erwinase Sales Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Indirect Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Erwinase Sales Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Erwinase Sales market is categorized based on

By Sales Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Application

• Acute Lymphoblastic Leukemia
• Pancreatic Cancer
• Gaucher Disease
• Hypersensitivity Reactions
• Others

By End User

• Adults
• Pediatrics
• Geriatrics
• Pregnant Women
• Others

By Distribution Channel

• Direct Sales
• Indirect Sales

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Jazz Pharmaceuticals
• Amgen
• Teva Pharmaceutical Industries
• Apobiologix
• Bristol-Myers Squibb
• Sanofi
• Eagle Pharmaceuticals
• Horizon Therapeutics
• Roche
• Pfizer
• Novartis
• Merck & Co.
• Genentech
• Celltrion
• Amgen